Relationship Between Expression of Stathmin, Survivin and Chemotherapy Effect of Docetaxel in Advanced Non-small Cell Lung Cancer

OBJECTIVE To investigate the relationship between expression of Stathmin, Survivin and chemotherapy effect of docetaxel in advanced non-small cell lung cancer. METHODS Seventy-two patients with advanced non-small cell lung cancer treating by docetaxel were enrolled in this study and their tumor samples were collected retrospectively for analysis. The expression of Stathmin, Survivin protein in tumor samples was detected by the immunohistochemical method. The data of therapeutical effect and toxicity were collected and analyzed. RESULTS The Stathmin positive staining accounted for 65.27%(47/72). The Survivin positive staining accounted for 76.38%(55/72). The response rate(CR+PR) was 51.38%. The efficiency of patients with over-expression of Stathmin(33.33%) was significant lower than patients with low-expression of Stathmin(66.67%)(P<0.05). The efficiency of patients with over-expression of Survivin(38.18%) was significant lower than patients with low-expression of Survivin(76.47%)(P<0.05). The efficiency, median progress time and 1-survival rate of patients with over-expression of Stathmin and Survivin(28.94%, 3.7 months, 29.9%) were all significant lower than patients with low-expression of Stathmin and Survivin(87.50%, 7.1 months, 62.5%)(P<0.05). The main side-effects were myelosuppression and digestive apparatus toxicity. CONCLUSION The expression of Stathmin and Survivin is associated with chemotherapy effect of docetaxel in advanced non-small cell lung cancer and can be used to detect the sensitivity.